2. Academic Validation
  3. Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328

Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328

  • ACS Med Chem Lett. 2011 Apr 18;2(7):498-502. doi: 10.1021/ml200018n.
Scott T Harrison 1,  James Mulhearn 1,  Scott E Wolkenberg 1,  Patricia J Miller 1,  Stacey S O'Malley 1,  Zhizhen Zeng 1,  David L Williams Jr 1,  Eric D Hostetler 1,  Sandra Sanabria-Bohórquez 1,  Linda Gammage 1,  Hong Fan 1,  Cyrille Sur 1,  J Christopher Culberson 1,  Richard J Hargreaves 1,  Jacquelynn J Cook 1,  George D Hartman 1,  James C Barrow 1
Affiliations

Affiliation

  • 1 Departments of Medicinal Chemistry, Imaging, and Chemical Modeling and Informatics, Merck Research Laboratories, Merck & Co., Inc. , P.O. Box 4, West Point, Pennsylvania 19486, United States.
PMID: 24900338 DOI: 10.1021/ml200018n
Abstract

5-Fluoro-2-aryloxazolo[5,4-b]pyridines were synthesized and investigated as potential (18)F containing β-amyloid PET ligands. In competition binding assays using human AD brain homogenates, compounds 14b, 16b, and 17b were identified as having favorable potency versus human β-amyloid plaque and were radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. These studies led to the identification of 17b (MK-3328) as a candidate PET ligand for the clinical assessment of β-amyloid plaque load.

Keywords

Alzheimer’s disease; PET; fluorine-18; oxazolo[5,4-b]pyridine; positron emission tomography; β-amyloid plaque.

Figures
Products